Provectus Biopharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 40.8% | 40.8% | -214.1% |
| FY2024 | 79.4% | 79.4% | -470.3% |
| FY2025 | 86.2% | 86.2% | -778.6% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 40.8% | 40.8% | -214.1% |
| FY2024 | 79.4% | 79.4% | -470.3% |
| FY2025 | 86.2% | 86.2% | -778.6% |